Associations of antiphospholipid antibodies, by isotype, in systemic lupus erythematosus.
| Factor | Antibody-negative, % | Antibody-positive, % | p | OR (95% CI) |
|---|---|---|---|---|
| IgM aCL | ||||
| Transient ischemic attack | 2 | 6 | 0.0389 | 2.44 (1.09–5.42) |
| Superficial thrombophlebitis | 4 | 5 | 0.5350 | 1.30 (0.60–2.83) |
| Deep venous thrombosis | 12 | 14 | 0.5515 | 1.14 (0.72–1.81) |
| Other venous thrombosis | 3 | 6 | 0.0738 | 1.95 (0.96–3.97) |
| Stroke | 7 | 10 | 0.3102 | 1.32 (0.76–2.28) |
| Myocardial infarction | 3 | 1 | 0.3110 | 0.45 (0.13–1.54) |
| IgG aCL | ||||
| Transient ischemic attack | 2 | 6 | 0.0381 | 2.47 (1.11–5.50) |
| Superficial thrombophlebitis | 3 | 5 | 0.1478 | 1.76 (0.83–3.71) |
| Deep venous thrombosis | 10 | 20 | 0.0005 | 2.21 (1.43–3.40) |
| Other venous thrombosis | 3 | 8 | 0.0045 | 2.89 (1.43–5.83) |
| Stroke | 7 | 11 | 0.1423 | 1.54 (0.90–2.63) |
| Myocardial infarction | 2 | 3 | 0.8044 | 1.11 (0.42–2.92) |
| IgA aCL | ||||
| Transient ischemic attack | 3 | 4 | 0.4757 | 1.43 (0.42–4.92) |
| Superficial thrombophlebitis | 4 | 4 | 0.7395 | 1.17 (0.35–3.97) |
| Deep venous thrombosis | 12 | 21 | 0.0538 | 1.92 (1.02–3.61) |
| Other venous thrombosis | 3 | 15 | 0.0002 | 5.26 (2.39–11.6) |
| Stroke | 8 | 13 | 0.1047 | 1.86 (0.88–3.96) |
| Myocardial infarction | 3 | 1 | 1.0000 | 0.55 (0.07–4.14) |
| IgM anti-ß2-GPI | ||||
| Transient ischemic attack | 3 | 7 | 0.0430 | 2.64 (1.11–6.27) |
| Superficial thrombophlebitis | 3 | 6 | 0.1220 | 1.99 (0.86–4.57) |
| Deep venous thrombosis | 13 | 12 | 1.0000 | 0.94 (0.52–1.69) |
| Other venous thrombosis | 4 | 5 | 0.6335 | 1.18 (0.48–2.92) |
| Stroke | 8 | 10 | 0.4729 | 1.27 (0.66–2.46) |
| Myocardial infarction | 3 | 1 | 0.2286 | 0.27 (0.04–2.06) |
| IgG anti-ß2-GPI | ||||
| Transient ischemic attack | 3 | 10 | 0.0374 | 3.69 (1.21–11.3) |
| Superficial thrombophlebitis | 3 | 12 | 0.0197 | 3.78 (1.37–10.4) |
| Deep venous thrombosis | 12 | 30 | 0.0013 | 3.33 (1.67–6.62) |
| Other venous thrombosis | 4 | 12 | 0.0293 | 3.36 (1.23–9.17) |
| Stroke | 8 | 16 | 0.0730 | 2.39 (1.02–5.61) |
| Myocardial infarction | 3 | 2 | 1.0000 | 0.91 (0.12–6.95) |
| IgA anti-ß2-GPI | ||||
| Transient ischemic attack | 3 | 6 | 0.0707 | 2.30 (1.00–5.31) |
| Superficial thrombophlebitis | 4 | 4 | 0.6466 | 1.20 (0.51–2.85) |
| Deep venous thrombosis | 11 | 20 | 0.0031 | 2.08 (1.31–3.30) |
| Other venous thrombosis | 4 | 4 | 0.8273 | 1.06 (0.45–2.49) |
| Stroke | 7 | 12 | 0.0502 | 1.79 (1.01–3.15) |
| Myocardial infarction | 3 | 1 | 0.3968 | 0.43 (0.10–1.87) |
| Lupus anticoagulant | ||||
| Transient ischemic attack | 2 | 7 | 0.0004 | 4.55 (1.98–10.4) |
| Superficial thrombophlebitis | 3 | 5 | 0.2212 | 1.63 (0.77–3.43) |
| Deep venous thrombosis | 6 | 27 | < 0.0001 | 5.91 (3.75–9.32) |
| Other venous thrombosis | 2 | 10 | < 0.0001 | 5.20 (2.48–10.9) |
| Stroke | 5 | 14 | < 0.0001 | 2.90 (1.72–4.89) |
| Myocardial infarction | 2 | 3 | 0.3228 | 1.61 (0.65–4.01) |
aCL: anticardiolipin antibodies; anti-ß2-GPI: anti-ß2 glycoprotein I.